Clinical Trials
2 trialsNCT00845039 2018-07-02
FC-4
Eli Lilly and Company
Phase 2 Terminated
NCT00503685 2018-06-06
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Eli Lilly and Company
Phase 2 Completed